2016
DOI: 10.5348/ijcri-201603-cl-10096
|View full text |Cite
|
Sign up to set email alerts
|

Rituximab-related posterior reversible encephalopathy syndrome in HUS patient post kidney transplant

Abstract: International Journal of Case Reports and Images (IJCRI) is an international, peer reviewed, monthly, open access, online journal, publishing high-quality, articles in all areas of basic medical sciences and clinical specialties.Aim of IJCRI is to encourage the publication of new information by providing a platform for reporting of unique, unusual and rare cases which enhance understanding of disease process, its diagnosis, management and clinico-pathologic correlations. IJCRI publishes Review

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

1
0
0

Year Published

2017
2017
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 30 publications
1
0
0
Order By: Relevance
“…Secondly, although our patient had uncontrolled pressures at the time of onset of symptoms, her symptoms did not resolve after adequate blood pressure control, which further supports the association of PRES with rituximab in this case. Treatment of PRES caused by rituximab, includes removal of the drug by plasmapheresis [10], which in our case, improved the symptoms of our patient. Thus, this case, like the various cases reported previously, shows a clear association of rituximab with PRES.…”
Section: Discussionsupporting
confidence: 51%
“…Secondly, although our patient had uncontrolled pressures at the time of onset of symptoms, her symptoms did not resolve after adequate blood pressure control, which further supports the association of PRES with rituximab in this case. Treatment of PRES caused by rituximab, includes removal of the drug by plasmapheresis [10], which in our case, improved the symptoms of our patient. Thus, this case, like the various cases reported previously, shows a clear association of rituximab with PRES.…”
Section: Discussionsupporting
confidence: 51%